NEW YORK--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced the grant of inducement
awards to 66 employees, as well as the grant of an inducement award to
Alvin Shih, M.D., the Company's Executive Vice President of Research and
Development. The awards were granted as an inducement material to each
such employee's entering into employment with Retrophin pursuant to Rule
5635(b)(4) of the NASDAQ Listing Rules. 66 employees were granted
inducement awards consisting of stock options to purchase an aggregate
of 2,014,500 shares of Retrophin common stock and 200,000 shares of
restricted common stock, and Dr. Shih was granted an inducement award
consisting of 230,000 shares of restricted common stock. The stock
options and restricted common stock generally vest in equal quarterly
installments over a period of three years. The stock options are
nonstatutory stock options and have an exercise price equal to the fair
market value of Retrophin's common stock on their grant date.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's approved products include Chenodal®,
Thiola® and Vecamyl®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
schizophrenia, infantile spasms, nephrotic syndrome and others. For
additional information, please visit www.retrophin.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Without limiting the foregoing, these
statements are often identified by the words "may", "might", "believes",
"thinks", "anticipates", "plans", "expects", "intends" or similar
expressions. No forward-looking statement can be guaranteed. You are
cautioned not to place undue reliance on these forward-looking
statements as there are important factors that could cause actual
results to differ materially from those in forward-looking statements,
many of which are beyond our control. The Company undertakes no
obligation to publicly update forward-looking statements, whether as a
result of new information, future events, or otherwise. Investors are
referred to the full discussion of risks and uncertainties as included
in the Company's filings with the Securities and Exchange Commission.
Retrophin, Inc.
Marc Panoff, 646-564-3671
CFO
marc@retrophin.com
or
Chris
Cline, 646-564-3680
Manager, Investor Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media